Skip to main content

InfuSystem Holdings, Inc

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

INFU$15.28+4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

-Unaudited Condensed Consolidated Statements of Cash Flows for the

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six Months Ended June 30,
(in thousands)20262025
OPERATING ACTIVITIES
Net income$4,248$2,332
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for doubtful accounts21239
Depreciation6,0456,166
Loss on disposal of and reserve adjustments for medical equipment502380
Gain on sale of medical equipment(96)(1,723)
Amortization of intangible assets384495
Amortization of deferred debt issuance costs4239
Stock-based compensation2,4751,769
Deferred income taxes1,0401,363
Changes in assets - (increase)/decrease:
Accounts receivable(5,689)(2,089)
Inventories593863
Other current assets(43)24
Other assets6371,106
Changes in liabilities - (decrease)/increase:
Accounts payable and other liabilities(2,603)(1,975)
NET CASH PROVIDED BY OPERATING ACTIVITIES7,7478,789
INVESTING ACTIVITIES
Acquisition of business—(1,412)
Purchase of medical equipment(6,543)(4,314)
Purchase of property and equipment(248)(348)
Proceeds from sale of medical equipment, property and equipment1,0081,728
NET CASH USED IN INVESTING ACTIVITIES(5,783)(4,346)
FINANCING ACTIVITIES
Principal payments on long-term debt(12,890)(30,261)
Cash proceeds from long-term debt13,64832,717
Debt issuance costs—(12)
Common stock repurchased as part of share repurchase program(4,358)(6,395)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans(775)(458)
Cash proceeds from exercise of options and ESPP189159
NET CASH USED IN FINANCING ACTIVITIES(4,186)(4,250)
Net change in cash and cash equivalents(2,222)193
Cash and cash equivalents, beginning of period3,186527
Cash and cash equivalents, end of period$964$720
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.